JP2016520573A5 - - Google Patents

Info

Publication number

JP2016520573A5

JP2016520573A5 JP2016510807A JP2016510807A JP2016520573A5 JP 2016520573 A5 JP2016520573 A5 JP 2016520573A5 JP 2016510807 A JP2016510807 A JP 2016510807A JP 2016510807 A JP2016510807 A JP 2016510807A JP 2016520573 A5 JP2016520573 A5 JP 2016520573A5

Authority

JP

Japan

Prior art keywords

composition

angiotensin

patient

composition according

hours

Prior art date

2014-04-25

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 239000000203 mixture Substances 0.000 claims description 52
• DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 36
• 210000002966 serum Anatomy 0.000 claims description 26
• 229940109239 creatinine Drugs 0.000 claims description 18
• 102000005862 Angiotensin II Human genes 0.000 claims description 17
• 101800000733 Angiotensin-2 Proteins 0.000 claims description 17
• CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 claims description 17
• 229950006323 angiotensin ii Drugs 0.000 claims description 13
• 208000001647 Renal Insufficiency Diseases 0.000 claims description 10
• 201000006370 kidney failure Diseases 0.000 claims description 10
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 8
• 208000019425 cirrhosis of liver Diseases 0.000 claims description 8
• 229910052708 sodium Inorganic materials 0.000 claims description 8
• 239000011734 sodium Substances 0.000 claims description 8
• 206010016654 Fibrosis Diseases 0.000 claims description 7
• 230000007882 cirrhosis Effects 0.000 claims description 7
• 230000036772 blood pressure Effects 0.000 claims description 6
• 239000008177 pharmaceutical agent Substances 0.000 claims description 6
• 102000015427 Angiotensins Human genes 0.000 claims description 5
• 108010064733 Angiotensins Proteins 0.000 claims description 5
• 238000002560 therapeutic procedure Methods 0.000 claims description 5
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 4
• 230000004872 arterial blood pressure Effects 0.000 claims description 4
• 230000024924 glomerular filtration Effects 0.000 claims description 4
• 238000007911 parenteral administration Methods 0.000 claims description 4
• 229910052700 potassium Inorganic materials 0.000 claims description 4
• 239000011591 potassium Substances 0.000 claims description 4
• 230000002485 urinary effect Effects 0.000 claims description 3
• SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims description 2
• PTKSEFOSCHHMPD-SNVBAGLBSA-N 2-amino-n-[(2s)-2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide Chemical compound COC1=CC=C(OC)C([C@H](O)CNC(=O)CN)=C1 PTKSEFOSCHHMPD-SNVBAGLBSA-N 0.000 claims description 2
• 108010072661 Angiotensin Amide Proteins 0.000 claims description 2
• VBTZKFAHKJXHBA-PIONDTTLSA-N acetic acid;(3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxy-2-phenylethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl Chemical compound CC(O)=O.C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 VBTZKFAHKJXHBA-PIONDTTLSA-N 0.000 claims description 2
• JYPVVOOBQVVUQV-CGHBYZBKSA-N angiotensinamide Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 JYPVVOOBQVVUQV-CGHBYZBKSA-N 0.000 claims description 2
• 201000011200 hepatorenal syndrome Diseases 0.000 claims description 2
• 238000001802 infusion Methods 0.000 claims description 2
• 238000002347 injection Methods 0.000 claims description 2
• 239000007924 injection Substances 0.000 claims description 2
• 238000001990 intravenous administration Methods 0.000 claims description 2
• 229960001094 midodrine Drugs 0.000 claims description 2
• 229960002748 norepinephrine Drugs 0.000 claims description 2
• SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims description 2
• 150000003839 salts Chemical class 0.000 claims description 2
• 239000004474 valine Substances 0.000 claims description 2
• 238000007689 inspection Methods 0.000 claims 1
• 210000002700 urine Anatomy 0.000 claims 1
• 238000000034 method Methods 0.000 description 29
• 238000012360 testing method Methods 0.000 description 2
• 238000010348 incorporation Methods 0.000 description 1
• 238000012552 review Methods 0.000 description 1